Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31370240 | 0.92 | FABP5 (0.41) | FABP5FABP7ITGB3ITGA2BPPARG | |
| SCHEMBL25357124 | 0.92 | FABP5 (0.42) | FABP5FABP7ITGB3ITGA2BPPARG | |
| SCHEMBL30686136 | 0.92 | FABP5 (0.42) | FABP5FABP7ITGB3ITGA2BPPARG | |
| SCHEMBL24633948 | 0.92 | FABP5 (0.42) | FABP5FABP7ITGB3ITGA2BPPARG | |
| SCHEMBL25360654 | 0.92 | FABP5 (0.42) | FABP5FABP7ITGB3ITGA2BPPARG | |
| SCHEMBL25360820 | 0.91 | ITGB3 (0.39) | FABP5FABP7ITGB3ITGA2BPPARG | |
| SCHEMBL25360816 | 0.91 | ITGB3 (0.39) | FABP5FABP7ITGB3ITGA2BPPARG | |
| SCHEMBL21994733 | 0.89 | FABP5 (0.40) | FABP5FABP7ITGB3ITGA2BPPARG | |
| SCHEMBL21994734 | 0.89 | FABP5 (0.40) | FABP5FABP7ITGB3ITGA2BPPARG | |
| SCHEMBL21838090 | 0.87 | ADAMTS5 (0.43) | FABP5FABP7ITGB3ITGA2BPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | FABP5 424/4885FABP7 508/4885ITGB3 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.